CAMBRIDGE, Mass., June 23, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy ...

Scholar Rock market cap hits $2.7bn after spinal muscular atrophy drug apitegromab clears a phase 3 trial, with filings now expected in Q1 2025.

Review the current valuation for Scholar Rock Holding Corp (SRRK:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

The Scholar Hotel, located in Edinburgh’s Southside, is celebrating the summer season with the official reopening of its ...

I met Mark Stewart once. It was on a platform at Clapham Junction, I wouldn’t normally approach a famous person like that, ...

Filmmaker Peter Jackson owns one of the largest private collections of bones of an extinct New Zealand bird called the moa.

A sneak peek at upcoming San Diego street fairs, festivals, concerts, performances, art shows, library events, community ...

The Bruce Springsteen Archives and Center for American Music's "Born to Run" symposium main event is Saturday, Sept. 6, at ...